TT01001

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

TT01001 is a selective agonist of mitoNEET and reduces oxidative stress injury and neuronal apoptosis by improving mitochondrial dysfunction. TT01001 can be used in studies about the treatment of type II diabetes.

TT01001 is a selective agonist of mitoNEET and reduces oxidative stress injury and neuronal apoptosis by improving mitochondrial dysfunction. TT01001 can be used in studies about the treatment of type II diabetes.(In Vivo):In type II diabetes model db/db mice, TT01001 improved hyperglycemia, hyperlipidemia, and glucose intolerance, and its efficacy was equivalent to that of pioglitazone, without the pioglitazone-associated weight gain. Mitochondrial complex II + III activity of the skeletal muscle was significantly increased in db/db mice. TT01001 significantly suppressed the elevated activity of the complex II + III.

TT-01001; TT 01001; Ethyl 4-(3-(3,5-dichlorophenyl)thioureido)piperidine-1-carboxylate

Others

Other Targets

RIP2

——

——

1022367-69-6

376.3

C15H19Cl2N3O2S

>98% (HPLC)

——

CCOC(=O)N1CCC(CC1)NC(=S)Nc1cc(Cl)cc(Cl)c1

——

(-20℃)

With Ice Pack

≥ 2 years